These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21491734)

  • 21. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
    Ridker PM; Rifai N; Rose L; Buring JE; Cook NR
    N Engl J Med; 2002 Nov; 347(20):1557-65. PubMed ID: 12432042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
    Gotto AM
    Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
    Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
    Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes.
    Abdelmouttaleb I; Danchin N; Ilardo C; Aimone-Gastin I; Angioï M; Lozniewski A; Loubinoux J; Le Faou A; Guéant JL
    Am Heart J; 1999 Feb; 137(2):346-51. PubMed ID: 9924170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome.
    Jahn J; Hellmann I; Maass M; Giannitsis E; Dalhoff K; Katus HA
    Herz; 2004 Dec; 29(8):795-801. PubMed ID: 15599677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease.
    Mitra B; Panja M
    J Assoc Physicians India; 2005 Jan; 53():25-32. PubMed ID: 15857009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.